Alaunos Therapeutics CEO resigns; Holger Weis appointed; audit committee shortfall triggers Nasdaq notice

Alaunos Therapeutics, Inc.

Dale Curtis Hogue Jr. resigned as CEO and director effective July 1, 2025; no disagreement.
Holger Weis appointed CEO July 2, 2025; $275,000 base salary; option for 130,000 shares at $5.06.
Weis resigned from audit and compensation committees, causing non-compliance with Nasdaq Rule 5605(c); company intends to use 180-day grace period.
Hogue entered consulting agreement at $250/hour for strategic advisory services.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.